Neurosurgical Guidelines
Tewarie et al. aim to offer a critical approach to the ethical and legal status of guidelines in neurosurgery. To this aim, the authors discuss: 1) the current state of neurosurgical guidelines and the evidence they are based on; 2) the degree of implementation of these guidelines; 3) the legal status of guidelines in medical disciplinary cases; and 4) the ethical balance between confident and critical use of guidelines. Ultimately, guidelines are neither laws that should always be followed nor purely academic efforts with little practical use. Every patient is unique, and tailored treatment defined by the surgeon will ensure optimal care; guidelines play an important role in creating a solid base that can be adhered to or deviated from, depending on the situation. From a research perspective, it is inevitable to rely on weaker evidence initially in order to generate more robust evidence later, and clinician-researchers have an ethical duty to contribute to generating and improving neurosurgical guidelines 1)
Anaesthetic and peri-operative management for thrombectomy procedures in stroke patients
Deep Brain Stimulation for Obsessive-Compulsive Disorder Guideline.
Evidence-based guideline for the prevention and management of perioperative infection
Gastric cancer intracranial metastases guidelines
Iatrogenic Pseudomeningocele Guidelines
Severe traumatic brain injury guidelines
Spontaneous Intracerebral Hemorrhage Guideline
Systematic Review and Meta-Analysis of Randomized Controlled Trials for Scalp Block in Craniotomy
Brain Trauma Foundation
ERAS Society
European Stroke Organisation (ESO)
European Thyroid Association
Congress of Neurological Surgeons
National Comprehensive Cancer Network
PRISMA guidelines
STROBE statement
Development
Quality
Links
2017 Infectious Diseases Society of America’s Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis
In 2017, the Infectious Diseases Society of America (IDSA) published guidelines for healthcare-associated ventriculitis treatment and meningitis treatment 2).
Spain
The analysis of surgical processes should be a standard of health systems.
Valero et al., describe the circuit of care and postoperative treatment for neurosurgical interventions in the centres of Spain.
From June to October 2014, a survey dealing with perioperative treatments and postoperative circuits after neurosurgical procedures was sent to the chiefs of Anaesthesiology of 73 Spanish hospitals with neurosurgery and members of the Neuroscience Section of SEDAR.
They obtained 45 responses from 30 centres (41.09%). Sixty percent of anaesthesiologists perform preventive locoregional analgesic treatment. Pain intensity is systematically assessed by 78%. Paracetamol, non-steroidal anti-inflammatory and morphine combinations are the most commonly used. A percentage of 51.1 are aware of the incidence of postoperative nausea after craniotomy and 86.7% consider multimodal prophylaxis to be necessary. Dexamethasone is given as antiemetic (88.9%) and/or anti-oedema treatment (68.9%). A percentage of 44.4 of anaesthesiologists routinely administer anticonvulsive prophylaxis in patients with supratentorial tumours (levetiracetam, 88.9%), and 73.3% of anaesthesiologists have postoperative surveillance protocols. The anaesthesiologist (73.3%) decides the patient's destination, which is usually ICU (83.3%) or PACU (50%). Postoperative neurological monitoring varied according to the type of intervention, although strength and sensitivity were explored in between 70-80%.
There is great variability in the responses, probably attributable to the absence of guidelines, different structures and hospital equipment, type of surgery and qualified personnel. We need consensual protocols to standardize the treatment and the degree of monitoring needed during the postoperative period 3).
Pharmaceutical company payments
Major pharmaceutical companies selling antihypertensive drug products in the Japanese market had a significant financial connection with the JSH2019 authors. Financial relationships between pharmaceutical companies and authors or Japanese medical societies are raising significant concerns about the credibility of clinical guidelines and the potentially biases and undue influences that they may cause, especially with respect to adverse prescription patterns 4).